|
|
Volumn 167 Suppl 3, Issue , 2012, Pages 3-11
|
|
Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL PRODUCT;
DERMATOLOGICAL AGENT;
HYBRID PROTEIN;
MONOCLONAL ANTIBODY;
FEMALE;
HEPATITIS B;
HEPATITIS C;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
METHODOLOGY;
PREGNANCY;
PREGNANCY COMPLICATION;
PREOPERATIVE CARE;
PSORIASIS;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
ANTIBODIES, MONOCLONAL;
BIOLOGICAL AGENTS;
DERMATOLOGIC AGENTS;
FEMALE;
HEPATITIS B, CHRONIC;
HEPATITIS C, CHRONIC;
HIV INFECTIONS;
HUMANS;
PREGNANCY;
PREGNANCY COMPLICATIONS;
PREOPERATIVE CARE;
PSORIASIS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RECOMBINANT FUSION PROTEINS;
|
|
EID: 84873438927
PISSN: None
EISSN: 13652133
Source Type: Journal
DOI: 10.1111/j.1365-2133.2012.11208.x Document Type: Review |
|
Times cited : (92)
|
|
References (0)
|
